Actively Recruiting
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Led by Ruijin Hospital · Updated on 2025-07-18
56
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, as well as preliminary efficacy of mRNA encoding CD19/CD3 T cell engager (ABO2203) in adult patients with relapsed or refractory CD19-positive B-NHL, This study included dose escalation and dose expansion parts.
CONDITIONS
Official Title
A Study of mRNA Encoding CD19/CD3 T Cell Engager (ABO2203) in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 years and 75 years of age at time of informed consent
- Histologically and/or cytologically confirmed relapsed or refractory CD19-positive B-cell non-Hodgkin lymphoma
- At least one evaluable or measurable target lesion per Lugano 2014 criteria
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- Life expectancy of 3 months or more
- Sufficient organ function
You will not qualify if you...
- Central nervous system lymphoma
- Previously undergone allogeneic hematopoietic stem cell transplantation or other organ transplants
- Any other prior malignancy active within the previous 5 years except cured skin basal cell cancer or carcinoma in situ of the cervix
- History of active autoimmune diseases
- History or current interstitial lung disease, tuberculosis, or other diseases affecting pulmonary function
- Uncontrolled diseases including diabetes, hypertension, active infections, active peptic ulcers, thromboembolic disease requiring anticoagulation
- Severe cardiovascular diseases
- History of severe allergies to protein-based drugs or any component of the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Ruijin Hospital
Shanghai, Shanghai Municipality, China, 200025
Actively Recruiting
Research Team
P
Pei miao Zhang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here